JCI insightHumansPsoriasisMaleFemaleAdult
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
David Strawn, James G Krueger, Robert Bissonnette, Kilian Eyerich, Laura K Ferris, Amy S Paller, Andreas Pinter, Dylan Richards, Elizabeth Y Chen, Kate Paget, Daniel Horowitz, Roohid Parast, Joshua J Rusbuldt, Jocelyn Sendecki, Sunita Bhagat
Published: 202510.1172/jci.insight.193563
Abstract
BACKGROUNDIcotrokinra is the first and only targeted oral peptide that selectively binds the IL-23 receptor with high affinity to precisely inhibit IL-23 signaling. Icotrokinra demonstrated high rates of complete skin clearance and durable disease co…
Preview only. Read the full abstract at the source